Rhelion Life Sciences Corp. RHEL
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.35M | -1.84M | -989.10K | -847.10K | -743.30K |
| Total Depreciation and Amortization | 73.10K | 58.00K | 61.10K | 71.10K | 65.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 420.10K | 1.18M | 416.70K | 210.50K | 185.30K |
| Change in Net Operating Assets | 213.10K | 268.80K | -63.10K | 16.10K | 201.10K |
| Cash from Operations | -642.30K | -336.00K | -574.50K | -549.40K | -291.30K |
| Capital Expenditure | -- | -1.70K | -2.30K | -1.80K | -95.50K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 31.70K | -- | -- | -- | -- |
| Divestitures | 134.20K | -- | -- | -- | -- |
| Other Investing Activities | -3.61M | -72.80K | -224.80K | -336.10K | -151.80K |
| Cash from Investing | -3.45M | -74.60K | -227.10K | -337.80K | -247.30K |
| Total Debt Issued | 24.90K | -176.90K | 176.60K | 0.00 | 4.90K |
| Total Debt Repaid | -55.50K | -25.40K | -25.10K | -33.80K | -686.30K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -22.10K | -147.50K | 108.70K | -24.60K | -492.50K |
| Foreign Exchange rate Adjustments | -132.50K | -500.00 | -16.30K | 20.20K | 30.80K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.24M | -558.60K | -709.10K | -891.60K | -1.00M |